Central diabetes insipidus: a previously unreported side effect of temozolomide.

@article{Faje2013CentralDI,
  title={Central diabetes insipidus: a previously unreported side effect of temozolomide.},
  author={Alexander T Faje and Lisa B. Nachtigall and Deborah J. Wexler and Karen Klahr Miller and Anne Klibanski and Hideo Makimura},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2013},
  volume={98 10},
  pages={3926-31}
}
CONTEXT Temozolomide (TMZ) is an alkylating agent primarily used to treat tumors of the central nervous system. We describe 2 patients with apparent TMZ-induced central diabetes insipidus. Using our institution's Research Patient Database Registry, we identified 3 additional potential cases of TMZ-induced diabetes insipidus among a group of 1545 patients treated with TMZ. CASE PRESENTATIONS A 53-year-old male with an oligoastrocytoma and a 38-year-old male with an oligodendroglioma each… CONTINUE READING